Antiepidermal Growth Factor Receptor Monoclonal Antibodies: Applications in Colorectal Cancer

Table 7

Trials using anti-EGFR MAbs with other targeted therapies in chemotherapy-resistant mCRC in KRAS WT patients.

Trial (author)	Phase	Protocol	Number enrolled	Results		HR (95% CI)	𝑃 value
				PFS	OS
AGITG CO.20; (Siu et al.) [31]	III	Cetuximab + brivanib alaninate; cetuximab	376; 374	5.0 mos.; 3.4 mos.	8.8 mos.; 8.1 mos.	PFS: 0.72 (0.62–0.84); OS: 0.88 (0.74–1.03)	<0.0001; 0.12
— (Watkins et al.) [32]	II/III	Dalotuzumab 10 mg/kg 1 week + cetuximab + irinotecan; versus	Total enrolled 345 WT	3.3 mos.	10.8 mos.	PFS: NR; OS: NR
		dalotuzumab 7.5 mg/kg q 2 weeks; versus		5.4 mos.	11.6 mos.
		placebo + cetuximab + irinotecan		5.6 mos.	14.0 mos.

WT: wild type, PFS: progression free survival, OS: overall survival, NR: not reported.